FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL OMB Number: 3235

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					$\overline{}$																
1. Name and Address of Reporting Person* SEIDENBERG BETH C							2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SEIDENBEKG BETH C						BCRX 1									Directo	r		10% Ov	vner		
							1						Officer below)	Officer (give title		Other (specify					
I							3. Date of Earliest Transaction (Month/Day/Year)											below)			
2190 PARKWAY LAKE DRIVE					05	05/17/2006															
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)										- 1 ′	Line) X Form filed by One Reporting Person										
BIRMING	GHAM A	AL	35244-)	- , , ,								
-															Form fi Person		e than	One Repor	ting		
(City) (State) (Zip)																					
		Ta	ble I - Nor	n-Deriv	ativ	e Se	curitie	s Ac	quirec	l, Dis	posed o	f, or I	3en	eficially	/ Owned						
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ear)	Execution if any	A. Deemed xecution Date, any Month/Day/Year)		3. 4. Securit Transaction Disposed Code (Instr. 5)			uired (Instr.	(A) or 3, 4 and	5. Amour Securitie Beneficia Owned F	s ally	Form:	Direct Indirect	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)		Price	Reported Transact (Instr. 3 a	Reported ransaction(s) Instr. 3 and 4)			(Instr. 4)			
			Table II -								osed of, convertib				Owned						
Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	ate, Ti	ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Year)	7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly [10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
Code V						(A)	(D)	Date Exercisa	ble	Expiration Date	Title		Amount or Number of Shares								
Stock Option	\$12.26	05/17/2006	05/17/20	06	A		15,000		06/17/20	06 ⁽¹⁾	05/17/2016	Comn		15,000	\$12.26	15,000		D			

Explanation of Responses:

1. Vest @ 1/12 per month over 12 months

Michael Richardson By POA 05/18/2006

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.